$ABT · Abbott Laboratories
Abbott Laboratories filed a Form 4 with the SEC on October 2, 2026, to report a change in beneficial ownership by Michael F. Roman, a director of the company. The filing shows that on September 30, 2026, Roman acquired 381 stock equivalent units at a price of $98.83 per unit. These units represent director fees that were credited to a stock equivalent unit account rather than paid in cash immediately.
According to the filing, the stock equivalent units earn the same return as if the fees had been invested in Abbott common shares. The account is generally paid in cash when Roman reaches age 65 or retires from the board. Following the reported transaction, Roman beneficially owned 7,166 stock equivalent units directly. The balance also includes additional units acquired through a dividend reinvestment feature. No common shares were bought or sold in this transaction.